Background. Patients with nephrotic syndrome have the highest lipoprotein(a) [Lp(a)] concentrations known. Lp(a) is an low-density lipoprotein (LDL)-like particle consisting of 45% cholesterol. The usual methods to determine LDL cholesterol do not distinguish between cholesterol derived from LDL and Lp(a) and are thus the net result of cholesterol levels from both lipoproteins. High Lp(a) concentrations therefore significantly contribute to the measured or calculated LDL cholesterol levels. Since statins have no influence on Lp(a) levels, it can be expected that the LDL cholesterol-lowering effect of statins may be diminished in patients who have a pronounced elevation of Lp(a) levels accompanied by only moderate elevations of LDL cholesterol.
Lipoprotein(a) [Lp(a)] has two faces. On one side, it is a lipoprotein which shows an independent effect on atherogenesis [1, 2] . On the other hand, the particle is very similar to low-density lipoprotein (LDL). It consists of an LDL particle to which the glycoprotein apolipoprotein(a) [apo(a)] is attached. This apolipoprotein shows a size polymorphism originating from a variable number of kringle IV (K-IV) repeats at the apo(a) gene locus [3, 4] . This polymorphism [5] is the most important determinant of Lp(a) levels which exhibit marked interindividual variation by more than 1000-fold. Individuals expressing a low number of K-IV repeats [low-molecularweight (LMW) apo(a) phenotypes] show on average markedly higher Lp(a) concentrations than those with a high number of K-IV repeats [high-molecular-weight (HMW) apo(a) phenotypes] who usually have low Lp(a) concentrations. There exists strong evidence that both LDL cholesterol and Lp(a) are risk factors for cardiovascular disease in the general population [6] . One of the major differences between both particles is the fact that LDL cholesterol can be effectively lowered by the widely used 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), while Lp(a) concentrations are resistant to this treatment [7] [8] [9] [10] [11] [12] [13] .
The usual methods to determine LDL cholesterol levels, including the calculation by the Friedewald formula do not distinguish between cholesterol derived from LDL and Lp(a) and therefore represent the sum of cholesterol from both lipoproteins. Since Lp(a) consists of about 45% cholesterol [14, 15] , the LDL cholesterol fraction will be overestimated when Lp(a) levels are very high. For instance, if a person has an Lp(a) level of 200 mg/dL, his or her LDL cholesterol fraction will be overestimated by 90 mg/dL. Since statins do not influence Lp(a) levels [7] [8] [9] [10] [11] [12] [13] , it can be expected that in those patients who have strikingly elevated Lp(a) levels and only mild to moderate elevation of LDL cholesterol the LDL cholesterollowering effect of statins will be masked, in contrast to patients with low Lp(a) levels. Moreover, since Lp(a) concentrations are particularly elevated in patients with small apo(a) isoforms, the LDL-lowering efficacy of statins might depend on the apo(a) size polymorphism.
Lp(a) levels are significantly elevated in patients with nephrotic syndrome [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . In the present study we investigated the Lp(a)-corrected LDL cholesterol concentrations in nephrotic patients. Based on the data we discuss the impact of the genetically determined apo(a) polymorphism on the response of measured LDL cholesterol and the impact on the indication for, and assessment of efficacy of intervention therapy.
METHODS Patients
We included 207 consecutive patients with nephrotic syndrome from the Department of Nephrology of the University of Innsbruck (N = 155), the Munich University Hospital and some outpatient clinics in Bavaria (N = 37), and the Department of Nephrology at the University of Düsseldorf (N = 15) as recently described [26] . Patients were included in the study when they underwent kidney biopsy and when they had at least one exact measurement of 24-hour protein excretion (>3.5 g/24 hours) and serum creatinine, if height and weight were available and if a fasting blood sample had been collected. Patients were carefully instructed for the 24-hour urine collection which was monitored by comparing the observed and expected 24-hour creatinine excretion by urine. Patients with diabetic nephropathy were excluded from the study. All patients were Caucasians and were not in need of renal replacement therapy. Patients were compared to 274 age-and gender-matched controls of the same ethnic origin without renal impairment or liver disease who were recruited in 1997 from one of the PROCAM study centers [27] . For clinical characteristics of patients and controls see Table 1 .
Laboratory procedures
Serum and ethylenediaminetetraacetic acid (EDTA) plasma were taken after a 12-hour overnight fast. After low-speed centrifugation, samples were frozen and kept at −80
• C prior to analysis [28] . We calculated the creatinine clearance using the formula of Cockcroft and Gault [29] . Measurement of lipids, serum albumin, Lp(a), and apo(a) phenotyping were performed centrally in a single laboratory to avoid interlaboratory differences in measurements. Measurements were done in batches to avoid a prolonged storage period before measurements. Total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides as well as albumin (bromo-cresol green method) were measured using kits from Roche (Mannheim, Germany) [30] . Measurements were made on microtiter plates as previously described [28] . LDL cholesterol was calculated with the Friedewald formula as follows:
The precipitation of apolipoprotein B (apoB)-containing lipoproteins for the measurement of HDL cholesterol in the supernatant results in an almost complete precipitation of Lp(a) particles. Only 0.38 mg/dL of Lp(a) particles on average remain in the supernatant (unpublished results). Thus, the Friedewald formula reveals both the LDL-and Lp(a)-derived cholesterol. We therefore calculated the Lp(a)-corrected LDL cholesterol by a modified version of the formula which considers that 45% of Lp(a) consists of cholesterol [14, 15] . This value differs from earlier studies which proposed 30% for correction and was recently determined by different methods and two independent study groups [14, 15] . This relative proportion is further supported by the observation that the lipid composition of LDL and LDL from Lp(a) is very similar [31] [32] [33] and the fact that LDL consists of rather 50% than 30% cholesterol. The modified formula is as follows:
Lp(a) quantification was performed as described in detail [28] with a double-antibody enzyme-linked immunosorbent assay (ELISA) using an affinitypurified polyclonal apo(a) antibody for coating and the horseradish peroxidase-conjugated monoclonal 1A2 for detection. An Lp(a)-positive serum from Technoclone (Vienna, Austria) with the same apo(a) isoforms served as standard throughout the study. Each sample was analyzed in duplicate, and intra-and interassay coefficients of variation were 2.7% and 6%, respectively. Apo(a) phenotyping was performed by sodium dodecyl sulfate-agarose gel electrophoresis (SDS agarose) under reducing conditions as outlined [34] .
Statistical procedures
Statistical analysis was performed with Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA) for Windows 11.0. Univariate comparisons of continuous variables between controls and nephrotic patients were done by unpaired t test or the nonparametric Wilcoxon rank sum test in case of nonnormally distributed variables. Dichotomized variables were compared using Pearson's v 2 test or the likelihood ratio v 2 -test. As in previous works from our and other groups [35] [36] [37] , we divided apo(a) phenotypes into two subgroups according to the molecular weight of the smaller apo(a) isoforms (discussed in [34] ). The LMW group included all subjects with at least one apo(a) isoform with 11 to 22 K-IV repeats (usually about 25% of a population); the high molecular weight (HMW) group comprised all subjects having only isoforms with more than 22 K-IV repeats.
RESULTS
The patients with the nephrotic syndrome had marked lipid abnormalities. They had strikingly elevated total and LDL cholesterol levels as well as triglyceride concentra- tions while HDL cholesterol levels were unchanged when compared to controls ( Table 2 ). The total/HDL cholesterol ratio was markedly elevated to 8.0 compared to 4.9 in controls. Patients with nephrotic syndrome showed a tremendous elevation of Lp(a) serum concentrations. The mean and median concentrations were three and five times higher, respectively, when compared to controls (mean 60.4 mg/dL vs. 20.0 mg/dL and median 29.8 mg/ dL vs. 6.4 mg/dL, respectively) ( Table 2 ) [26] . About 30% of the patients had Lp(a) levels above 70 mg/dL. This could only be observed in 8.4% of the controls. Since Lp(a) consists of 45% cholesterol, we expected that a significant proportion of LDL cholesterol in nephrotic patients was accounted for by Lp(a) particles. We therefore corrected the LDL cholesterol levels derived from the Friedewald formula by subtracting 45% of the measured Lp(a) concentrations. These corrected LDL cholesterol levels were only 9 mg/dL lower in controls when compared to the uncorrected levels. In patients with nephrotic syndrome, however, the difference was more than 27 mg/dL ( Table 2) . The difference was three times greater in patients with LMW compared to patients with HMW apo(a) phenotypes (47.8 ± 51.8 mg/dL vs. 15.7 ± 21.1 mg/dL, P < 0.001) (Fig. 1) . Forty-three out of 74 patients (58%) with LMW apo(a) phenotypes showed Lp(a)-corrected LDL cholesterol levels which were at least 30 mg/dL lower than the uncorrected LDL cholesterol levels. The frequency was significantly lower in patients with HMW apo(a) phenotypes (21 out of 133 patients, 16%; P < 0.00001) (Fig. 2) . Finally, we considered how many of the investigated patients would have to be considered for therapeutic intervention based on the LDL cholesterol concentrations according to the Adult Treatment Panel III (ATP III) guidelines [38] and the recommendation of the National Kidney Foundation [39] . Both recommendations define an LDL cholesterol target of <100 mg/dL. Almost all of the patients (94.7%) would have needed intervention irrespective of the apo(a) phenotype groups (95.9% and 93.9% for patients with LMW and HMW apo(a) phenotypes, respectively). When Lp(a)-corrected LDL cholesterol levels were used the proportion of patients requiring intervention was much lower for patients with LMW apo(a) phenotypes (70.3%) but remained almost unchanged for patients with HMW apo(a) phenotypes (91.7%). Twenty-two of the total patient group (10.6%) changed from the group matching the intervention criteria (LDL cholesterol level ≥100 mg/dL) to the one failing to match the criteria (corrected LDL cholesterol below 100 mg/dL). This was seen 11 times more frequently in Abbreviations are: Apo(a), apolipoprotein(a); LMW, low molecular weight; HMW, high molecular weight; LDL, low-density lipoprotein; Lp(a), lipoprotein(a).
a Patients from the previous study [40] .
patients with LMW than in those with HMW apo(a) phenotypes (25.6% vs. 2.2%, P < 0.00001) ( Table 3 ) (Fig. 3) . We also calculated the frequency of patients meeting the intervention criteria in hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) patients who had participated in an earlier study [40] (Table 3) . On CAPD the proportion of patients meeting the intervention criteria was slightly lower. The effect of the apo(a) size polymorphism was directionally similar to that seen in nephrotic patients. In 22.2% of the patients with LMW compared to 3.3% of those with HMW apo(a) types the indication was changed when Lp(a)-corrected LDL cholesterol levels were used. The proportion was less among hemodialysis patients and the effect of the apo(a) size polymorphism was less pronounced than in nephrotic patients and CAPD patients (Table 3) .
DISCUSSION
Although the highly atherogenic Lp(a) is an LDL-like particle it is, unfortunately, not influenced by the widely used lipid-lowering statins [7] [8] [9] [10] [11] [12] [13] . Therefore, the LDL cholesterol-lowering effects of statins would not be very promising in case of a combination of mild to moderate elevated LDL cholesterol and excessively elevated Lp(a) levels. Since the absolute reductions in LDL cholesterol are smaller at lower levels of LDL cholesterol [41] , a nonresponder or a low-responder to treatment might be hidden behind extremely elevated Lp(a) concentrations. In this case a major amount of LDL cholesterol derives from Lp(a) and simulates an LDL cholesterol value mandatory to be treated although the Lp(a)-corrected and therefore treatable LDL cholesterol is below 100 mg/dL. This situation is relatively rare in the general Caucasian population but occurs more often in African Americans with two-to threefold higher Lp(a) levels than Caucasians [42] , in CAPD patients [40, 43, 44] , or in patients with nephrotic syndrome [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . In nephrotic patients carrying an LMW apo(a) phenotype we can even observe Lp(a) levels up to 300 to 600 mg/dL which corresponds to Lp(a)-corrected LDL cholesterol levels 135 to 270 mg/dL lower than the uncorrected LDL cholesterol levels. Our observation has three implications. First, if a study aims to investigate the efficacy of the LDL cholesterollowering effect of a statin, it will be more accurate to consider and monitor only the amount of LDL cholesterol which is accessible for intervention. This can have a considerable influence on the results. Let us consider a not so rarely observed nephrotic patient with an Lp(a) concentration of 200 mg/dL and a total LDL cholesterol of 200 mg/dL and therefore an Lp(a)-corrected LDL cholesterol of 110 mg/dL. If in this case a statin leads to only 30 mg/dL reduction of LDL cholesterol, the effectiveness will be either 15% or 27% depending whether total or Lp(a)-corrected LDL cholesterol is used for calculation.
Second, guidelines from the National Kidney Foundation (K/DOQI) recently classified chronic kidney disease as coronary heart disease risk equivalent [45] . According to the ATP III guidelines, a coronary heart disease risk equivalent carries a risk for a major coronary event equal to that of established coronary heart disease (i.e., >20% per 10 years) [38] . In presence of coronary heart disease or a coronary heart disease risk equivalent, the LDL cholesterol goal is below 100 mg/dL which should be achieved by therapeutic lifestyle changes and/or lipidlowering drug therapy. However, 25.6% of all nephrotic patients with LMW apo(a) phenotypes would be classified as no longer to be in need of lipid-lowering intervention, when Lp(a)-corrected LDL cholesterol instead of total LDL cholesterol is used for therapeutic decision. Since this is very rarely observed in patients with HMW apo(a) phenotypes (2.2%), a pharmacogenetic effect caused by the apo(a) polymorphism can be assumed. To be precise we should better call it a "pseudopharmacogenetic" effect since it is simulated by incorrectly measured (calculated) LDL cholesterol levels. The situation is very similar in CAPD patients (22.2% vs. 3.3%) who have besides nephrotic patients one of the highest pathologic Lp(a) levels [40, 43] . It is less pronounced in hemodialysis patients (15.4% vs. 9.8%) which can be explained by the less intensive elevation of Lp(a) when compared to CAPD patients and by the apo(a) phenotype-dependent elevation of Lp(a) described earlier (Table 3) [36, 43, 46] .
Third, clinical recommendations and guidelines are mostly based on the results of intervention studies. These studies when focused on cholesterol, however, based their analysis usually on total LDL cholesterol and not on Lp(a)-corrected LDL cholesterol levels since most studies up to now did not use a modified Friedewald formula. The question is whether the therapeutic goal (LDL cholesterol <100 mg/dL) would change if Lp(a)-corrected LDL cholesterol levels were used especially in a group of patients with tremendously elevated Lp(a) levels such as patients with nephrotic syndrome. Due to the lack of multiple randomized controlled trials in kidney patients, guidelines in these patients are mostly based on the results from the general population where we usually do not observe these high Lp(a) levels. Very soon such studies in kidney patients will be available and will be the basis for future guidelines. These studies have the chance to perform the analysis of the data in both ways and to adjust the goals accordingly if advantageous.
We do not expect that this observation has a major impact on the general Caucasian population which has usually not such high Lp(a) levels. This is supported by a recent study which showed that the relative risk for ischemic heart disease is almost the same when the LDL cholesterol is calculated by the classical Friedewald formula or by the modified formula which corrects for Lp(a)-derived LDL cholesterol [47] . Nevertheless, rare cases with markedly elevated Lp(a) levels (e.g., >150 mg/dL) might be responsible for nonresponders or low-responders to statins when LDL cholesterol is only moderately elevated. In addition, our observation might be particularly important in patients of African American origin who present generally with much higher Lp(a) levels [42, 44] .
Recently, Scanu and Hinman [8] investigated the influence of statins on hypercholesterolemic subjects with high Lp(a) levels and observed in some cases an Lp(a)-corrected LDL cholesterol decrease as low as 10 mg/dL. The decrease of the Lp(a)-corrected LDL cholesterol levels was proportional to the pretreatment ratio of the Lp(a)-corrected LDL cholesterol to Lp(a) concentrations. That means that the decrease of LDL cholesterol was strongly dependent on the accessible LDL cholesterol demonstrating that only cholesterol from LDL cholesterol and not Lp(a) is affected by statin therapy [8] . Ongoing large trials in renal patients will provide the possibility to study such an effect easily in the setting of renal disease. If our suggestion is confirmed by these studies, about 25% of all renal patients with an LMW apo(a) phenotype would not have to undergo lipid-lowering therapy by statins when the indication for the therapy is only made by the goals of lipid-lowering. Furthermore, in cases of nonresponders or low-responders with this constellation it might not be useful to increase the dosage of statins. Whether the pleiotropic effects of statins including an anti-inflammatory action through a reduction of oxidative stress, nuclear factor-jB (NF-jB) activation, intercellular adhesion molecule-1 (ICAM-1) expression and macrophage infiltration [48] are sufficiently advantageous in this subgroups compared to the risk of side-effects might be answered by the same studies. Nevertheless, it can already be helpful at this stage to calculate the Lp(a)-corrected LDL cholesterol levels if a particular patient does not respond sufficiently to statin therapy. If high Lp(a) levels are indeed the cause for a disappointing LDL cholesterol-lowering effect of a statin, such a patient might benefit from alternative therapies which were reported to lower Lp(a) levels. Those are a treatment with the nicotinic acid analogue niceritrol which showed pronounced Lp(a)-lowering effects in chronic renal disease and hemodialysis patients [49, 50] or a combination therapy of an extended-release niacin with a statin [51] which might probably add the pleiotropic effects of the latter.
Limitations of the study
Due to the repetitive K-IV motif of apo(a), a recent study showed some evidence that Lp(a) is overestimated in subjects with HMW apo(a) isoforms if measured by an assay which uses antibodies directed against the K-IV motif [52] . If our assay would indeed overestimate Lp(a) in HMW apo(a) isoforms this would result in even lower values of Lp(a)-derived LDL cholesterol in patients with HMW apo(a) phenotypes and therefore an even stronger "pseudopharmacogenetic" effect.
CONCLUSION
We show in this investigation that a considerable amount of LDL cholesterol in patients with nephrotic syndrome derives from Lp(a) and that this strongly depends on the apo(a) polymorphism. Since the Lp(a)-derived LDL cholesterol can not be modulated by statins, a markedly higher frequency of patients with LMW than with HMW apo(a) phenotypes would be classified to be no longer in need of lipid-lowering therapy by statins when Lp(a)-corrected LDL cholesterol instead of total LDL cholesterol is used for therapeutic decision.
NOTE ADDED IN PROOF
Because triglyceride levels above 400 mg/dL influence the Friedewald formula, we excluded in an additional subanalysis 23 patients and 5 control patients with these high triglyceride levels. Nevertheless, we observed virtually the same Lp(a)-derived LDL cholesterol and Lp(a)-corrected LDL cholesterol levels as presented in Table  1 . Furthermore, the frequency of nephrotic patients who have to be considered for therapeutic intervention remained almost the same as presented in Table 3 .
